DOCSLIB.ORG

Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2017 Public Instrument 7 of 2017 Published in Gazette No. 1836 of 02 June 2017 NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES (CONSOLIDATION) (AMENDMENT OF SCHEDULE) ORDER 2017 The Administrator makes the following Order in exercise of the powers under section 3(2) of the Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006(a). Short title and commencement 1. This Order may be cited as the Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2017. 2. This Order comes into force on 12 June 2017. Substitution of First Schedule (controlled drugs) 3. For the First Schedule(b) to the Narcotic Drugs and Psychotropic Substances (Consolidation) Ordinance 2006 substitute the Schedule contained in the Schedule to this Order. Revocations 4. The following instruments are revoked— (a) the Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2011(c); (b) the Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2015(d). (a) Ordinance 16/2006 as amended by Ordinances 22/2010 and 2/2011. (b) The First Schedule was substituted by P.I. 30/2011 and amended by P.I. 4/2015. (c) P.I. 30/2011. (d) P.I. 4/2015. SCHEDULE SCHEDULE TO BE SUBSTITUTED FOR THE FIRST SCHEDULE Article 3 “FIRST SCHEDULE Section 3 Controlled Drugs PART I Class A Drugs 1. The following substances and products— Name of substance or product Other names Comments Acetorphine Acetylmethadol Acetyl-α-methylfentanyl Also falls under paragraph 4 Alfentanil Also falls under paragraph 4 Ally(α-methyl-3,4- MDAL Also falls under paragraph 6 methylenedioxyphenethyl)amine Allylprodine Alpha-acetylmethadol Alpha-meprodine Alpha-methadol Alpha-Methyl-3,4- MDPL Also falls under paragraph 6 methylenedioxyphenethyl(prop-2- ynyl)amine Alpha-Methyl-4-(methylthio) Also falls under paragraph 6 phenethylamine Alpha-methylfentanyl Also falls under paragraph 4 Alpha-methylthiofentanyl Also falls under paragraph 4 Alpha-prodine Amphetamine Also falls under paragraph 6 Anileridine Benzethidine Benzyl(α-methyl-3,4- MDBZ Also falls under paragraph 6 methylenedioxyphenethyl)amine 2 Benzylmorphine 3-benzylmorphine Beta-2,5-Trimethoxy-4- BOD Also falls under paragraph 6 methylphenethylamine Beta-3,4,5- BOM Also falls under paragraph 6 Tetramethoxyphenethylamine Beta-acetylmethadol Beta-hydroxy-3-methylfentanyl (a) Ohmefentanyl Also falls under paragraph 4 (b) OMF Beta-hydroxyfentanyl Also falls under paragraph 4 Beta-meprodine Beta-methadol Beta-Methoxy-3,4- BOH Also falls under paragraph 6 methylenedioxyphenethylamine Beta-prodine Bezitramide Brolamphetamine (a) DOB Also falls under paragraph 6 (b) Dimethoxybromoamphetamine (c) Bromo-DMA (d) 2,5-Dimethozy-4- bromoamphetamine Bromo-benzodifuranyl-isopropylamine (a) BDF Also falls under paragraph 6 (b) Bromo-dragonfly Bufotenine (a) N,N-dimethylserotonin Also falls under paragraph 5 (b) 5-OH DMT (c) 5-hydroxy-N,N- Dimethyltyptamine Cannabinol derivatives Cannabinol, except where contained in cannabis or cannabis resin Cathinone (a) Benzoylethanamine Excluded from Part II (Class B Drugs) (b) β-keto-amphetamine See paragraph 11 of Part II Clonitazene Cocaleaf Cocaine 3 Codoxime Cyclopropylmethyl(α-methyl -3,4- MDCPM Also falls under paragraph 6 methylenedioxyphenethyl)amine Desomorphine Krokodil Dexamfetamine Also falls under paragraph 6 Dextromoramide Diamorphine (a) Diacetylmorphine (b) Heroin Diampromide Diethylthiambutene Difenoxin Dihydroetorphine Dihydromorphine Dimenoxadol Dimepheptanol (a) Methadol (b) Racemethadol Dimethyl(α-methyl-3,4- (a) MDDM Also falls under paragraph 6 methylenedioxyphenethyl)amine (b) MDDMA Dimethylthiambutene Dioxaphetyl butyrate Diphenoxylate Dipipanone Pipadone Drotebanol Oxymethebanol Ecgonine and any derivative of ecgonine which is convertible to ecgonine or to cocaine Ethylmethylathiambutene Eticyclidine PCE Excluded from Part II (Class B Drugs) See paragraph 18 of Part II Etonitazene Excluded from Part II (Class B Drugs) See paragraph 15 of Part II 4 Etorphine Etoxeridine Fentanyl Also falls under paragraph 4 Furethidine 4-phenylpiperidine Hydrocodone Hydromorphinol Hydromorphone Hydroxypethidine Isomethadone Isoamidone Ketobemidone Levamfetamine Also falls under paragraph 6 Levomethorphan Levomoramide Levophenacylmorphan Levorphanol Levomethamfetamine Also falls under paragraph 6 Lofentanyl Also falls under paragraph 4 Lysergamide andotherN- alkylderivatives of lysergamide Lysergic AcidDiethylamide (a) LSD (b) Lysergide Metazocine Methadone Methadyl acetate Methamfetamine Metamfetamine Also falls under paragraph 6 Methamfetamineracemate Metamfetamineracemate Also falls under paragraph 6 Methcathinone 2-(methylamin)-1- Excluded from Part II (Class B phenylpropanone-1 Drugs) See paragraph 11 of Part II Methyldesorphine Methyldihydromorphine 5 Metopon 5-methyldihydromorphone Morpheridine Morphine Morphine methylbromide Morphine methobromide Morphine-N-oxide and other pentavalent nitrogen morphine derivatives Myrophine Myristylbenzylmorphine N-(4-Ethylthio-2,5- Also falls under paragraph 6 dimethoxyphenthyl)hydroxylamine N-(4-sec-Butylthio-2,5- Also falls under paragraph 6 dimethoxyphenethyl)hydroxylamine N,α-Dimethyl-3,4- MDMA Also falls under paragraph 6 (methylenedioxy)phenethylamine Nalbuphine N-ethyl-α-methyl-3,4- (a) MDE Also falls under paragraph 6 (methylenedioxy)phenethylamine (b) N-ethyl MDA (c) MDEA N-HydroxyMDA (±)-N-[α-methyl-3,4- Also falls under paragraph 6 (methylenedioxy)phenylethyl] hydroxylamine Nicomporphine 3,6-dinicotinylmorphine N-Methyl-1-(4-Methoxyphenyl)-2- (a) PMMA Also falls under paragraph 6 aminopropane (b) Paramethoxymethylampheta mine N-Methyl-N-(α-methyl-3,4- Also falls under paragraph 6 methylenedioxyphenethyl)hydroxyl amine Noracymethadol Norlevorphanol Normethadone Normorphine Norpipanone O-Methyl-N-(α-methyl-3,4- Also falls under paragraph 6 methylenedioxyphenethyl)hydroxyl amine 6 Opium Oripavine Oxycodone Oxymorphone 14-Hydroxydihydro morphinone Para-fluorofentanyl Also falls under paragraph 4 Parahexyl n-hexyl-Δ3THC Pentazocine Pethidine Meperidine Pethidine Intermediate A 4-phenylpiperidine Pethidine Intermediate C Pethidinic acid Pethidine Intermediate B Norpethidine Phenadoxone Phenampromide Phenazocine Phenomorphan Phenoperidine Piminodine Piritramide p-Methoxy-α-methylphenethylamine PMA Also falls under paragraph 6 p-Methylthioamphetamine Also falls under paragraph 6 Poppy-straw Papaver Somniferum Proheptazine Properidine Psilocin Psilocybine Racemethorphan Racemoramide Racemorphan 7 Remifentanyl Rolicyclidine PCPy Excluded from Part II (Class B Drugs) See paragraph 18 of Part II Sufentanil Tenocyclidine (a) TCP (b) 1-{1-(2- Thienyl)cyclohexyl}piperidine Thebacon Thebaine Thiofentanyl Also falls under paragraph 4 Tilidine Tilidate Trimeperidine Tryptamine Also falls under paragraph 5 Zipeprol α,α-Dimethyl-3,4- MDMP Also falls under paragraph 6 methylenedioxyphenethyl(methyl)a mine α,α-Dimethyl-3,4- MDPH Also falls under paragraph 6 methylenedioxphenethylamine 1-(1-benzofuranyl-2)-N-methylpropan- 2-MAPB Also falls under paragraph 8 2-amine 1-(1-benzofuranyl-2)propan-2- 2-APB Also falls under paragraph 8 amine 1-(2-Phenylethyl)-4-phenyl-4- (a) 1-phenethyl-4-phenyl-4- acetoxypiperidine piperidinol acetate(ester) (b) PEPAP 1-(3,4- Also falls under paragraph 6 Methylenedioxybenzyl)butyl(methyl) amine 1-methyl-4-phenyl-4- (a) MPPP propionoxypiperidine (b) Desmethylprodine (c) 1-methyl-4-pheynl-4- piperidinol propionate(ester) 2-(1,4-Dimethoxy-2-naphthyl)-1- Also falls under paragraph 6 methylethylamine 2-(1,4-Dimethoxy-2- Also falls under paragraph 6 8 naphthyl)ethylamine 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro- Also falls under paragraph 6 2-naphthyl)-1-melhylethylamine 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro- Also falls under paragraph 6 2-napthyl)ethylamine 2-(1,4-Methano-5,8-dimethoxy- Also falls under paragraph 6 1,2,3,4-tetrahydro-6-naphthyl)-1- methylethylamine 2-(1,4-Methano-5,8-dimethoxy- Also falls under paragraph 6 1,2,3,4-tetrahydro-6- naphthyl)ethylamine 2-(2,5-Dimethoxy-4- methylphenyl)cyclopropylamine 2-(4,7-Dimethoxy-2,3-dihydro-1H- Also falls under paragraph 6 indan-5-yl)-1-methylethylamine 2-(4,7-Dimethoxy-2,3-dihydro-1H- Also falls under paragraph 6 indan-5-yl)ethylamine 2-(5-Methoxy-2,2-dimethyl-2,3- Also falls under paragraph 6 dihydrobenzo[b]furan-6-yl)-1- methylethylamine 2-(5-Methoxy-2-methyl-2,3- Also falls under paragraph 6 dihydrobenzo[b]furan-6-yl)-1- methylethylamine 2-(α-Methyl-3,4- Also falls under paragraph 6 methylenedioxyphenethylamino)et hanol 2,4,5-trimethoxyamphetamine TMA-2 Also falls under paragraph 6 2,4,6-trimethoxyamphetamine TMA-6 Also falls under paragraph 6 2,5-dimethoxy-4(n)- 2-C-T-7 Also falls under paragraph 6 propylthiophenethylamine 2,5-dimethoxy-4-(β-propylthio)-N- HOT-7 Also falls under paragraph 6 hydroxyphenethylamine 2,5-dimethoxy-4- 2C-B Also falls under paragraph 6 bromophenethylamine 2,5-Dimethoxy-4- (a) STP Also falls under paragraph 6 dimethylphenethylamine (b) DOM 2,5-dimethoxy-4- 2C-T-2 Also falls under paragraph 6 ethyliopehnethylamine 2,5-dimethoxy-4- 2C-I Also falls under paragraph 6 iodophenethylamine 9 2,5-dimethoxy-α- DMA Also falls under paragraph 6 Methylphenethylamine 2-Amino-1-(2,5-dimethoxy-4- BOHD Also falls under paragraph 6 methylphenyl)ethanol 2-Amino-1-(3,4- DME Also falls under paragraph 6 dimethoxyphenyl)ethanol 2-amino-4-methyl-5-phenyl-2- (a) 4-MAR Oxazoline (b) 4-Methylaminorex 2-Fluoromethamphetamine (a) 2-FMA Also falls under paragraph 6 (b) o-Fluoromethamphetamine 2-Methoxy-α-methyl-4,5-
Load more

Recommended publications
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • KHAT Latest Revision: June 11, 2005
    KHAT Latest Revision: June 11, 2005 O CH3 NH2 Cathinone OH CH3 NH2 Cathine N CH3 H3C N 3,6-dimethyl-2,5-diphenylpyrazine (dimer of Cathinone) 1. SYNONYMS CFR: Cathinone Cathine CAS #: Cathinone Hydrochloride: 71031-15-7 Cathine Hydrochloride: 2153-98-2 Cathine Base: 492-39-7 Other Names: Catha edulis Kat Mutsawhari Mutsawari Mdimamadzi Musitate Mirungi Miraa Ol meraa Tumayot Liruti Ikwa Arabian Tea 2. CHEMICAL AND PHYSICAL DATA Khat is used as a stimulant or as a medicine in parts of Africa and the Arabian Peninsula. The plant is thought to have been in cultivation before the coffee plant; historical references date the use of the plant to the fourteenth century. Peter Forsskal, a physician and botanist, collected khat specimens in an expedition organized by the King of Denmark in the eighteenth century. Forsskal assigned the name Catha edulis to the plant. The effects produced by the drug include excitation, hypersensitivity, anorexia, insomnia, euphoria, increased respiration, and hyperthermia. These effects closely parallel the effects of d-amphetamine. Khat is a bush or tree that grows naturally in the humid mountainous regions (elevations of 5000 to 6500 feet) of East and South Africa. The trees can grow naturally to over 60 ft; however, cultivated khat trees are pruned and their height to kept to approximately 16 feet. Khat also grows to a height of 3 feet as a small bush in arid regions. Like opium, the alkaloid content of khat will vary with the soil, climatic conditions, and cultivation. Khat belongs to the genus Catha edulis. It is recognized that the genus consists of only one species; however, the plant exhibits extreme polymorphism.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants
    MedDocs Publishers ISSN: 2638-1370 Annals of Clinical Nutrition Open Access | Mini Review Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants Ali Zaid A Alshehri1,2*; Mohammed saeed Al Qahtani1,3; Mohammed Aedh Al Qahtani1,4; Abdulhadi M Faeq1,5; Jawad Aljohani1,6; Ammar AL-Farga7 1Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia 2Poison Control and Medical Forensic Chemistry Center, Ministry of Health, Riyadh, Saudi Arabia 3Khammis Mushayte Maternity & Children Hospital, Ministry of Health, Saudi Arabia 4Ahad Rufidah General, Hospital, Aseer, Ministry of Health, Saudi Arabia 5Comprehensive Specialized Clinics of Security Forces in Jeddah, Ministry of Interior, Saudi Arabia 6Compliance Department, Yanbu Health Sector, Ministry of Health, Saudi Arabia 7Department of Biochemistry, Faculty of Science, University of Jeddah, Saudi Arabia *Corresponding Author(s): Ali Zaid A Alshehri Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia Email: [email protected] Received: Apr 27, 2020 Accepted: Jun 05, 2020 Published Online: Jun 10, 2020 Journal: Annals of Clinical Nutrition Publisher: MedDocs Publishers LLC Online edition: http://meddocsonline.org/ Copyright: © Alshehri AZA (2020). This Article is distributed under the terms of Creative Commons Attribution 4.0 International License Introduction ATS are synthetic compounds belonging to the class of stimu- and heroin users combined [3,4]. Fenethylline, 7-(2-amethyl lants that excite the Central Nervous System (CNS) to produce phenyl-amino ethyl)-theophylline, is a theophylline derivative of adrenaline-like effects such as amphetamine, methamphet- amphetamine. It is a psychoactive drug which is similar to am- amine, fenethylline, methylphenidate and dextroamphetamine phetamine in many ways [5].
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Renaissance in Psychedelic Research: What Do Preclinical Models Have 2 to Offer
    CHAPTER The renaissance in psychedelic research: What do preclinical models have 2 to offer Kevin S. Murnane1 Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, United States 1Corresponding author: Tel.: +1-678-547-6290; Fax: +1-678-547-6423, e-mail address: [email protected] Abstract Human research with psychedelics is making groundbreaking discoveries. Psychedelics mod- ify enduring elements of personality and seemingly reduce anxiety, depression, and substance dependence in small but well-designed clinical studies. Psychedelics are advancing through pharmaceutical regulatory systems, and neuroimaging studies have related their extraordinary effects to select brain networks. This field is making significant basic science and translational discoveries, yet preclinical studies have lagged this renaissance in human psychedelic research. Preclinical studies have a lot to offer psychedelic research as they afford tight control of experimental parameters, subjects with documented drug histories, and the capacity to elucidate relevant signaling cascades as well as conduct invasive mechanistic studies of neurochemistry and neural circuits. Safety pharmacology, novel biomarkers, and pharmaco- kinetics can be assessed in disease state models to advance psychedelics toward clinical practice. This chapter documents the current status of psychedelic research, with the thematic argument that new preclinical studies would benefit this field. Keywords Psychedelic, Preclinical, Serotonin, Neuroimaging, Alcoholism, Anxiety, Depression, Substance dependence 1 INTRODUCTION The term psychedelic has come to be associated with a broad class of drugs with diverse chemical, pharmacological, and psychoactive effects. Alternative nomencla- tures have used hallucinogen, entheogen, psychotomimetic and other appellations to Progress in Brain Research, Volume 242, ISSN 0079-6123, https://doi.org/10.1016/bs.pbr.2018.08.003 25 © 2018 Elsevier B.V.
    [Show full text]
  • 124.204 Schedule I — Substances Included. 1. Schedule I Shall Consist
    1 , §124.204 124.204 Schedule I — substances included. 1. Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetylmethadol. b. Allylprodine. c. Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM). d. Alphameprodine. e. Alphamethadol. f. Alpha-Methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine). g. Benzethidine. h. Betacetylmethadol. i. Betameprodine. j. Betamethadol. k. Betaprodine. l. Clonitazene. m. Dextromoramide. n. Difenoxin. o. Diampromide. p. Diethylthiambutene. q. Dimenoxadol. r. Dimepheptanol. s. Dimethylthiambutene. t. Dioxaphetyl butyrate. u. Dipipanone. v. Ethylmethylthiambutene. w. Etonitazene. x. Etoxeridine. y. Furethidine. z. Hydroxypethidine. aa. Ketobemidone. ab. Levomoramide. ac. Levophenacylmorphan. ad. Morpheridine. ae. Noracymethadol. af. Norlevorphanol. ag. Normethadone. ah. Norpipanone. ai. Phenadoxone. aj. Phenampromide. ak. Phenomorphan. al. Phenoperidine. am. Piritramide. an. Proheptazine. ao. Properidine. ap. Propiram. aq. Racemoramide. ar. Tilidine. as. Trimeperidine. at. Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)- 3-methyl-4-piperidinyl]-N-phenylpropanamide). Thu May 19 07:35:43 2016 Iowa Code 2016, Section 124.204 (25, 1) §124.204, 2 au. Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide). av.
    [Show full text]
  • Texas Controlled Substances Act
    HEALTH AND SAFETY CODE TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES CHAPTER 481. TEXAS CONTROLLED SUBSTANCES ACT SUBCHAPTER A. GENERAL PROVISIONS Sec.A481.001.AASHORT TITLE. This chapter may be cited as the Texas Controlled Substances Act. Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989. Sec.A481.002.AADEFINITIONS. In this chapter: (1)AA"Administer" means to directly apply a controlled substance by injection, inhalation, ingestion, or other means to the body of a patient or research subject by: (A)AAa practitioner or an agent of the practitioner in the presence of the practitioner; or (B)AAthe patient or research subject at the direction and in the presence of a practitioner. (2)AA"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of a carrier or warehouseman acting in the usual and lawful course of employment. (3)AA"Commissioner" means the commissioner of state health services or the commissioner 's designee. (4)AA"Controlled premises" means: (A)AAa place where original or other records or documents required under this chapter are kept or are required to be kept; or (B)AAa place, including a factory, warehouse, other establishment, or conveyance, where a person registered under this chapter may lawfully hold, manufacture, distribute, dispense, administer, possess, or otherwise dispose of a controlled substance or other item governed by the federal Controlled Substances Act (21 U.S.C.
    [Show full text]
  • Stimulant and Related Medications: US Food and Drug
    Stimulant and Related Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for stimulant and related medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved dosages and indications for the use of stimulant and related medications in adults are provided in this table. All medication doses listed are for oral administration. Information on the generic availability of the stimulant and related medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Dosing Information Other Information Availability amphetamine/dextroamphetamine ADHD Initial dose: May increase daily dose by 5 mg at Yes mixed salts[1] 5 mg once or twice a day; weekly intervals until optimal response Maximum dose: 40 mg per day is achieved. Only in rare cases will it be necessary to exceed a total of 40 mg per day. amphetamine/dextroamphetamine narcolepsy Initial dose: 10 mg per day; May increase daily dose by 10 mg at Yes mixed salts Usual dose: weekly intervals until optimal response 5 mg to 60 mg per day is achieved. Take first dose in divided doses upon awakening. amphetamine/dextroamphetamine ADHD Recommended dose: Patients switching from regular-release Yes mixed salts ER*[2] 20 mg once a day amphetamine/dextroamphetamine mixed salts may take the same total daily dose once a day. armodafinil[3] narcolepsy Recommended dose: Take as a single dose in the morning.
    [Show full text]
  • MDAI (5,6Methylenedioxy2aminoindane
    human psychopharmacology Hum. Psychopharmacol Clin Exp 2013; 28: 345–355. Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/hup.2298 SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H- cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update John M Corkery1,3*, Simon Elliott2, Fabrizio Schifano1,3, Ornella Corazza3 and A Hamid Ghodse1,† 1National Programme for Substance Abuse Deaths (np-SAD), International Centre for Drug Policy, St George’s, University of London, London, UK 2ROAR Forensics Ltd, Malvern, Worcestershire, UK 3School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, UK Objectives MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’)isa psychoactive substance, sold primarily over the Internet and in ‘head’ shops as a ‘legal high’. Synthesised and used as a research chemical in the 1990s, MDAI has structural similarities to MDMA (3,4-methylenedioxy-N-methylamphetamine) and shares its behavioural properties. Recreational use of MDAI appears to have started in Europe around 2007, with a noticeable increase after 2009 in the UK and other countries. Calls to National Poisons Information Services started in 2010, although there were few presentations to emergency departments by patients complaining of undesirable physical and psychiatric effects after taking MDAI. Recreational use of this drug has been reported only occa- sionally by online user fora. There is little scientifically based literature on the pharmacological, physiological, psychopharmacological, tox- icological and epidemiological characteristics of this drug. Methods Recent literature (including ‘grey’) was searched to update what is known about MDAI, especially on its toxicity.
    [Show full text]